Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reevaluation of Qianlieshutong capsule for chronic prostatitis (real-world, multicenter, single-arm)
ChiCTR2200057068Phase 4Not yet recruiting
- Sponsor
- Yunnan Provincial Hospital of Traditional Chinese Medicine
- Start
- Mar 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Qianlieshutong in chronic prostatitis (CP), sponsored by Yunnan Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: NIH-CPSI score, Symptom grading quantitative score and 4 more. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
Qianlieshutong
03
Conditions
chronic prostatitis (CP)
Beyond the preview
Go deeper on ChiCTR2200057068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057068.